CME credits: 1.00

Valid until: 28-12-2023

Claim your CME credit at https://reachmd.com/programs/cme/when-to-start-using-sglt2i-in-hfref-initiating-guideline-recommended-treatment-options/14735/

What are the benefits of SGLT2 inhibitors (SGLT2i) in heart failure? What clinical challenges can physicians face when initiating guideline recommended therapy in heart failure? And what unanswered questions with SGLT2i in heart failure remain? Three speakers present the guidelines, evidence of studies and tell us what we can expect in the near future with regard to SGLT2i in heart failure.

This course consists of the following:

• Chapter 1: The clinical challenges of initiating guideline recommended therapy in HF - Prof. John McMurray, MD - Glasgow, UK
• Chapter 2: Benefits and evolving insights on SGLT2i in the spectrum of LVEF - Prof. Carolyn Lam, MD, PhD - Singapore
• Chapter 3: Expanding evidence on SGLT2i: Where are we now and what can we expect? - Prof. Scott Solomon, MD - Boston, MA, USA

=